Clinical Trial

A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of a Single Suspension Injection of Investigational Capsid Inhibitors Compared to Placebo in Healthy Adults

Completed Phase 1
View on ClinicalTrials.gov →
Summary
The primary purpose of the study is to investigate safety and tolerability following single and multiple ascending subcutaneous (SC) and intramuscular (IM) doses of capsid inhibitors in healthy participants. The study will also describe the pharmacokinetics following single and multiple ascending SC and IM doses of capsid inhibitors in healthy participants.
Protocol Amendment History 1 change
critical Trial completed 2026-08-06
Trial Details
NCT Number NCT06012136
Lead Sponsor ViiV Healthcare
Conditions HIV Infections
Enrollment 85 participants
Start Date 2023-08-24
Primary Completion 2026-06-09 (estimated)
Study Completion 2026-06-09 (estimated)
Updated on ClinicalTrials.gov 2026-08-05